News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
489,572 Results
Type
Article (9512)
Company Profile (143)
Press Release (479914)
Multimedia
Podcasts (25)
Webinars (7)
Section
Business (167988)
Career Advice (334)
Deals (26009)
Drug Delivery (19)
Drug Development (53675)
Employer Resources (27)
FDA (9925)
Job Trends (8888)
News (240327)
Policy (18231)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (1)
Academia (517)
Accelerated approval (28)
ADA (18)
Adcomms (2)
Allergies (99)
Alliances (33442)
ALS (114)
Alzheimer's disease (1022)
Antibody-drug conjugate (ADC) (301)
Approvals (10561)
Artificial intelligence (344)
ASCO (163)
Autoimmune disease (226)
Automation (29)
Bankruptcy (265)
Belgium (1)
Best Places to Work (7184)
BIO (37)
Biologics (9)
BIOSECURE Act (2)
Biosimilars (153)
BioSpace Insights (20)
Biotechnology (91)
Bispecific (1)
Bladder cancer (139)
Brain cancer (33)
Breast cancer (518)
Cancer (3883)
Cardiovascular disease (231)
Career advice (270)
Career pathing (2)
CAR-T (187)
CDC (2)
CDMO (29)
Celiac Disease (1)
Cell therapy (507)
Cervical cancer (35)
Clinical research (48652)
Collaboration (1309)
Commercialization (4)
Compensation (1533)
Complete response letters (38)
COVID-19 (802)
CRISPR (64)
C-suite (832)
Cystic fibrosis (92)
Data (5900)
Denatured (4)
Depression (120)
Dermatology (70)
Diabetes (360)
Diagnostics (4232)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (169)
Drug pricing (37)
Drug shortages (4)
Duchenne muscular dystrophy (172)
Earnings (73995)
Editorial (8)
Employer branding (8)
Employer resources (24)
Events (88609)
Executive appointments (727)
FDA (12690)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (25)
Funding (976)
Gene editing (128)
Generative AI (13)
Gene therapy (354)
GLP-1 (341)
Government (1075)
Grass and pollen (2)
Guidances (281)
Healthcare (9419)
Hematology (106)
HIV (56)
Huntington's disease (25)
IgA nephropathy (68)
Immunology and inflammation (156)
Immuno-oncology (64)
Indications (162)
Infectious disease (997)
Inflammatory bowel disease (137)
Inflation Reduction Act (5)
Influenza (85)
Intellectual property (261)
Interviews (41)
IPO (12462)
IRA (9)
Job creations (2028)
Job search strategy (257)
JPM (12)
Kidney cancer (16)
Labor market (14)
Layoffs (85)
Leadership (1)
Legal (5273)
Licensing (18)
Liver cancer (45)
Longevity (21)
Lung cancer (548)
Lymphoma (299)
Machine learning (29)
Management (5)
Manufacturing (597)
Marketing (8)
MASH (121)
Medical affairs (2)
Medical device (8691)
Medtech (8850)
Mergers & acquisitions (14627)
Metabolic disorders (770)
mRNA (70)
Multiple sclerosis (109)
NASH (4)
Neurodegenerative disease (256)
Neuropsychiatric disorders (60)
Neuroscience (1982)
NextGen: Class of 2026 (3221)
Non-profit (870)
Now hiring (57)
Obesity (263)
Opinion (29)
Ovarian cancer (172)
Pain (181)
Pancreatic cancer (207)
Parkinson's disease (228)
Partnered (13)
Patents (509)
Patient recruitment (531)
Patient selection (2)
Peanut (32)
People (41685)
Peptides (2)
Pharmaceutical (31)
Pharmacy benefit managers (13)
Phase 1 (15675)
Phase 2 (21723)
Phase 3 (14813)
Pipeline (7778)
Policy (41)
Postmarket research (1580)
Preclinical (6598)
Press Release (34)
Prostate cancer (195)
Psychedelics (24)
Radiopharmaceuticals (195)
Rare diseases (619)
Real estate (3059)
Recruiting (12)
Regenerative medicine (2)
Regulatory (15204)
Reports (26)
Research institute (614)
Resumes & cover letters (46)
Rett syndrome (42)
RNA editing (7)
RSV (49)
Schizophrenia (125)
Series A (170)
Series B (125)
Service/supplier (5)
Sickle cell disease (64)
Special edition (7)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2060)
Stomach cancer (3)
Supply chain (52)
Tariffs (14)
The Weekly (20)
Vaccines (346)
Venture capital (31)
Weight loss (103)
Women's health (88)
Worklife (1)
Date
Today (52)
Last 7 days (299)
Last 30 days (1445)
Last 365 days (19413)
2026 (13871)
2025 (19541)
2024 (23300)
2023 (26775)
2022 (34939)
2021 (37473)
2020 (33768)
2019 (23584)
2018 (17762)
2017 (19013)
2016 (18167)
2015 (24448)
2014 (21841)
2013 (18228)
2012 (20236)
2011 (20441)
2010 (20332)
Location
Africa (247)
Alabama (77)
Alaska (2)
Arizona (312)
Arkansas (11)
Asia (18242)
Australia (2133)
California (12419)
Canada (3261)
China (563)
Colorado (500)
Connecticut (431)
Delaware (215)
Europe (25611)
Florida (1856)
Georgia (394)
Hawaii (3)
Idaho (46)
Illinois (841)
India (63)
Indiana (333)
Iowa (17)
Japan (432)
Kansas (103)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1234)
Massachusetts (8142)
Michigan (316)
Minnesota (574)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (12)
Nevada (122)
New Hampshire (61)
New Jersey (2717)
New Mexico (12)
New York (2918)
North Carolina (1327)
North Dakota (4)
Northern California (6226)
Ohio (297)
Oklahoma (14)
Oregon (17)
Pennsylvania (2308)
Puerto Rico (21)
Rhode Island (31)
South America (426)
South Carolina (79)
South Dakota (1)
Southern California (5162)
Tennessee (131)
Texas (2011)
United States (40282)
Utah (374)
Vermont (1)
Virginia (168)
Washington D.C. (45)
Washington State (957)
West Virginia (1)
Wisconsin (76)
Wyoming (1)
489,572 Results for "abbvie inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to BMO Capital Markets.
September 4, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.
May 20, 2026
·
2 min read
·
Tristan Manalac
Earnings
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
July 31, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
August 18, 2026
·
6 min read
Press Releases
AbbVie Completes Acquisition of Apogee Therapeutics
September 3, 2026
·
8 min read
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
March 9, 2026
·
2 min read
·
Heather McKenzie
Press Releases
AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
September 15, 2026
·
4 min read
Mergers & acquisitions
AbbVie strikes $10.9B Apogee buy to challenge juggernaut Dupixent
AbbVie will add Apogee’s IL-13 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug Humira.
June 22, 2026
·
2 min read
·
Tristan Manalac
CAR-T
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this space. Eli Lilly, AbbVie, AstraZeneca and more are up for the challenge.
July 27, 2026
·
8 min read
·
Tristan Manalac
Earnings
AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate
Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position of “ample financial capacity.”
April 29, 2026
·
3 min read
·
Gabrielle Masson
1 of 48,958
Next
